The European Commission (EC) has granted marketing authorization for Zinbryta (daclizumab) to treat adults with relapsing forms of multiple sclerosis (RMS).
Zinbryta is a once-monthly, self administered, subcutaneous injection and is marketed by US firms Biogen (Nasdaq: BIIB) and AbbVie (NYSE: ABBV).
Clinical data has suggested that Zinbryta offers a valuable new option with RMS, showing that it significantly reduced relapses, 24-week confirmed disability progression and new brain lesions for up to three years compared to Biogen’s Avonex (interferon beta-1a) intramuscular injection.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze